Morgan Stanley Maintains a Buy Rating on Medibank Private Ltd. (MDBPF)

The company’s shares closed last Tuesday at $2.10.

According to, Laaman is a 1-star analyst with an average return of -3.5% and a 37.5% success rate. Laaman covers the Healthcare sector, focusing on stocks such as Ramsay Health Care, Cochlear Limited, and CSL.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Medibank Private Ltd. with a $2.35 average price target, which is an 11.9% upside from current levels. In a report issued on June 22, Jarden also maintained a Buy rating on the stock with a price target.

See the top stocks recommended by analysts >>

Based on Medibank Private Ltd.’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $0. In comparison, last year the company had a net profit of $0.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Medibank Private Ltd. engages in the underwriting and distribution of private health insurance policies through Medibank and ahm brands. It operates through Health Insurance, and Medibank Health segments. The Health Insurance segment offers private health insurance products including hospital cover and ancillary cover, as stand-alone products and packaged products. The Medibank Health segment offers a range of activities including contracting with government and corporate customers to provide health management services, as well as providing a range of telehealth services in Australia. The company was founded in 1976 and is headquartered in Docklands, Australia.

Read More on MDBPF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More